Genetic basis of attenuation of dengue virus type 4 small plaque mutants with restricted replication in suckling mice and in SCID mice transplanted with human liver cells.

Mutations that restrict replication of dengue virus have been sought for the generation of recombinant live-attenuated dengue virus vaccines. Dengue virus type 4 (DEN4) was previously grown in Vero cells in the presence of 5-fluorouracil, and the characterization of 1248 mutagenized, Vero cell passaged clones identified 20 temperature-sensitive (ts) mutant viruses that were attenuated (att) in suckling mouse brain (J. E. Blaney, Jr., D. H. Johnson, C. Y. Firestone, C. T. Hanson, B. R. Murphy, and S. S. Whitehead, 2001, J. Virol. 75(20), 9731-9740). The present investigation has extended these studies by identifying an additional 22 DEN4 mutant viruses which have a small plaque size (sp) phenotype in Vero cells and/or the liver cell line, HuH-7. Five mutant viruses have a sp phenotype in both Vero and HuH-7 cells, three of which are also ts. Seventeen mutant viruses have a sp phenotype in only HuH-7 cells, 13 of which are also ts. Each of the sp viruses was growth restricted in the suckling mouse brain, exhibiting a wide range of reduction in replication (9- to 100,000-fold). Complete nucleotide sequence was determined for the 22 DEN4 sp mutant viruses, and nucleotide substitutions were found in the 3'-untranslated region (UTR) as well as in all coding regions except NS4A. Identical mutations have been identified in multiple virus clones, suggesting that they may be involved in the adaptation of DEN4 virus to efficient growth in Vero cells. Six of the 22 sp 5-FU mutant viruses lacked coding mutations in the structural genes, and 17 recombinant DEN4 viruses were generated which separately encoded each of the mutations observed in these six sp viruses. Analysis of the recombinant DEN4 viruses defined the genetic basis of the sp, ts, and att phenotypes observed in the six sp viruses. Mutations in NS1, NS3, and the 3'-UTR were found to confer a greater than 100-fold, 10,000-fold, and 1000-fold reduction in replication of rDEN4 virus in SCID mice transplanted with HuH-7 cells, respectively, which serves as a novel small animal model for DEN4 infection.

[1]  A. Nisalak,et al.  A prospective study of dengue infections in Bangkok. , 1988, The American journal of tropical medicine and hygiene.

[2]  M. St. Claire,et al.  Attenuation of the recombinant human parainfluenza virus type 3 cp45 candidate vaccine virus is augmented by importation of the respiratory syncytial virus cpts530 L polymerase mutation. , 1999, Virology.

[3]  A. Pletnev Infectious cDNA clone of attenuated Langat tick-borne flavivirus (strain E5) and a 3' deletion mutant constructed from it exhibit decreased neuroinvasiveness in immunodeficient mice. , 2001, Virology.

[4]  A. Davidson,et al.  Mutagenesis of the Dengue Virus Type 2 NS3 Protein within and outside Helicase Motifs: Effects on Enzyme Activity and Virus Replication , 2001, Journal of Virology.

[5]  C. Huang,et al.  Chimeric Dengue Type 2 (Vaccine Strain PDK-53)/Dengue Type 1 Virus as a Potential Candidate Dengue Type 1 Virus Vaccine , 2000, Journal of Virology.

[6]  R. Karron,et al.  A live attenuated recombinant dengue-4 virus vaccine candidate with restricted capacity for dissemination in mosquitoes and lack of transmission from vaccinees to mosquitoes. , 2001, The American journal of tropical medicine and hygiene.

[7]  M. Bray,et al.  Infectious RNA transcribed from stably cloned full-length cDNA of dengue type 4 virus. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[8]  D. Mosier,et al.  Human xenograft models for virus infection. , 2000, Virology.

[9]  J. An,et al.  Development of a novel mouse model for dengue virus infection. , 1999, Virology.

[10]  F. Guirakhoo,et al.  Construction, Safety, and Immunogenicity in Nonhuman Primates of a Chimeric Yellow Fever-Dengue Virus Tetravalent Vaccine , 2001, Journal of Virology.

[11]  A. Patwari,et al.  Hepatic dysfunction in childhood dengue infection. , 2000, Journal of tropical pediatrics.

[12]  E. Holmes,et al.  Secondary structure of the 3' untranslated region of flaviviruses: similarities and differences. , 1997, Nucleic acids research.

[13]  D. Vaughn,et al.  A live attenuated dengue-1 vaccine candidate (45AZ5) passaged in primary dog kidney cell culture is attenuated and immunogenic for humans. , 1994, The Journal of infectious diseases.

[14]  A. Barrett,et al.  Genetic variation in the 3' non-coding region of dengue viruses. , 2001, Virology.

[15]  A. Mazzei Molecular biology of dengue virus , 1998 .

[16]  R. Chanock,et al.  Dengue type 4 virus mutants containing deletions in the 3' noncoding region of the RNA genome: analysis of growth restriction in cell culture and altered viremia pattern and immunogenicity in rhesus monkeys , 1996, Journal of virology.

[17]  G. Kadaré,et al.  Virus-encoded RNA helicases , 1997, Journal of virology.

[18]  S. Wahid,et al.  A comparison of the pattern of liver involvement in dengue hemorrhagic fever with classic dengue fever. , 2000, The Southeast Asian journal of tropical medicine and public health.

[19]  W. Bancroft,et al.  Selection of attenuated dengue 4 viruses by serial passage in primary kidney cells. V. Human response to immunization with a candidate vaccine prepared in fetal rhesus lung cells. , 1984, The American journal of tropical medicine and hygiene.

[20]  F. Guirakhoo,et al.  Recombinant Chimeric Yellow Fever-Dengue Type 2 Virus Is Immunogenic and Protective in Nonhuman Primates , 2000, Journal of Virology.

[21]  D. Vaughn,et al.  West Nile virus/dengue type 4 virus chimeras that are reduced in neurovirulence and peripheral virulence without loss of immunogenicity or protective efficacy , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[22]  A. Pletnev,et al.  Attenuation of the Langat tick-borne flavivirus by chimerization with mosquito-borne flavivirus dengue type 4. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[23]  L. Rosen,et al.  Detection of dengue virus RNA by reverse transcription-polymerase chain reaction in the liver and lymphoid organs but not in the brain in fatal human infection. , 1999, The American journal of tropical medicine and hygiene.

[24]  Duane J. Gubler,et al.  Dengue and Dengue Hemorrhagic Fever , 1998, Clinical Microbiology Reviews.

[25]  P. Marianneau,et al.  Report of a fatal case of dengue infection with hepatitis: demonstration of dengue antigens in hepatocytes and liver apoptosis. , 1999, Human pathology.

[26]  P. Young,et al.  Immunolocalization of the dengue virus nonstructural glycoprotein NS1 suggests a role in viral RNA replication. , 1996, Virology.

[27]  A. Pletnev,et al.  Growth-restricted dengue virus mutants containing deletions in the 5' noncoding region of the RNA genome. , 1995, Virology.

[28]  A. Allison,et al.  Dengue viruses and mononuclear phagocytes. II. Identity of blood and tissue leukocytes supporting in vitro infection , 1977, The Journal of experimental medicine.

[29]  T. Yamane,et al.  Growth of human hepatoma cells lines with differentiated functions in chemically defined medium. , 1982, Cancer research.

[30]  M. Aye,et al.  Risk factors in dengue shock syndrome. , 1997, The American journal of tropical medicine and hygiene.

[31]  R. Chanock,et al.  A further attenuated derivative of a cold-passaged temperature-sensitive mutant of human respiratory syncytial virus retains immunogenicity and protective efficacy against wild-type challenge in seronegative chimpanzees. , 1994, Vaccine.

[32]  D. Vaughn,et al.  Testing of a dengue 2 live-attenuated vaccine (strain 16681 PDK 53) in ten American volunteers. , 1996, Vaccine.

[33]  C. King,et al.  Study of Dengue Virus Infection in SCID Mice Engrafted with Human K562 Cells , 1998, Journal of Virology.

[34]  D. Stone,et al.  The 5' noncoding region and virulence of poliovirus vaccine strains. , 1994, Trends in microbiology.

[35]  Peter F. Stadler,et al.  Spontaneous and Engineered Deletions in the 3′ Noncoding Region of Tick-Borne Encephalitis Virus: Construction of Highly Attenuated Mutants of a Flavivirus , 1998, Journal of Virology.

[36]  F. Murphy,et al.  Immunization against Viral Diseases , 1968 .

[37]  S. Watowich,et al.  Molecular and biological changes associated with HeLa cell attenuation of wild-type yellow fever virus. , 1999, Virology.

[38]  A. Nisalak,et al.  Early clinical and laboratory indicators of acute dengue illness. , 1997, The Journal of infectious diseases.

[39]  J. S. Porterfield Exotic Viral Infections , 1998, Nature Medicine.

[40]  B. Murphy,et al.  Paired Charge-to-Alanine Mutagenesis of Dengue Virus Type 4 NS5 Generates Mutants with Temperature-Sensitive, Host Range, and Mouse Attenuation Phenotypes , 2002, Journal of Virology.

[41]  R. Padmanabhan,et al.  The Serine Protease and RNA-Stimulated Nucleoside Triphosphatase and RNA Helicase Functional Domains of Dengue Virus Type 2 NS3 Converge within a Region of 20 Amino Acids , 1999, Journal of Virology.

[42]  C. Rice,et al.  Genetic analysis of the yellow fever virus NS1 protein: identification of a temperature-sensitive mutation which blocks RNA accumulation , 1997, Journal of virology.

[43]  P. Marianneau,et al.  Liver histopathology and biological correlates in five cases of fatal dengue fever in Vietnamese children , 2001, Virchows Archiv.

[44]  D. L. Harris,et al.  Partial purification and characterization of a dengue virus soluble complement-fixing antigen. , 1970, Journal of immunology.

[45]  W. Bancroft,et al.  Lack of attenuation of a candidate dengue 1 vaccine (45AZ5) in human volunteers. , 1987, The American journal of tropical medicine and hygiene.

[46]  D. Vaughn,et al.  Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3'-untranslated region. , 2001, The American journal of tropical medicine and hygiene.

[47]  J P Griffith,et al.  Hepatitis C virus NS3 RNA helicase domain with a bound oligonucleotide: the crystal structure provides insights into the mode of unwinding. , 1998, Structure.

[48]  W. Bancroft,et al.  Dengue virus type 2 vaccine: reactogenicity and immunogenicity in soldiers. , 1984, The Journal of infectious diseases.

[49]  B. Murphy,et al.  A single nucleotide substitution in the transcription start signal of the M2 gene of respiratory syncytial virus vaccine candidate cpts248/404 is the major determinant of the temperature-sensitive and attenuation phenotypes. , 1998, Virology.

[50]  Y. Liaw,et al.  Liver biochemical tests and dengue fever. , 1992, The American journal of tropical medicine and hygiene.

[51]  Takemoto Kk Plaque mutants of animal viruses. , 1966 .

[52]  P. Russell,et al.  Dengue-2 vaccine: preparation from a small-plaque virus clone , 1980, Infection and immunity.

[53]  M. Bray,et al.  Construction of intertypic chimeric dengue viruses by substitution of structural protein genes. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[54]  B. Murphy,et al.  Chemical Mutagenesis of Dengue Virus Type 4 Yields Mutant Viruses Which Are Temperature Sensitive in Vero Cells or Human Liver Cells and Attenuated in Mice , 2001, Journal of Virology.

[55]  C. Mandl,et al.  Adaptation of Tick-Borne Encephalitis Virus to BHK-21 Cells Results in the Formation of Multiple Heparan Sulfate Binding Sites in the Envelope Protein and Attenuation In Vivo , 2001, Journal of Virology.

[56]  W. Bancroft,et al.  Virulence of a live dengue virus vaccine candidate: a possible new marker of dengue virus attenuation. , 1988, The Journal of infectious diseases.

[57]  R. Chanock,et al.  The nucleotide sequence of dengue type 4 virus: analysis of genes coding for nonstructural proteins. , 1987, Virology.

[58]  R. Chanock,et al.  Satisfactorily attenuated and protective mutants derived from a partially attenuated cold-passaged respiratory syncytial virus mutant by introduction of additional attenuating mutations during chemical mutagenesis. , 1994, Vaccine.

[59]  N. Bhamarapravati,et al.  Live attenuated tetravalent dengue vaccine. , 2000, Vaccine.

[60]  D. Gubler,et al.  Impact of dengue/dengue hemorrhagic fever on the developing world. , 1999, Advances in virus research.

[61]  D. Vaughn,et al.  Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers. , 2001, Vaccine.

[62]  C. Huang,et al.  Attenuation Markers of a Candidate Dengue Type 2 Vaccine Virus, Strain 16681 (PDK-53), Are Defined by Mutations in the 5′ Noncoding Region and Nonstructural Proteins 1 and 3 , 2000, Journal of Virology.

[63]  E. Koonin,et al.  A new superfamily of putative NTP‐binding domains encoded by genomes of small DNA and RNA viruses , 1990, FEBS letters.